{
    "pmcid": "11666439",
    "qa_pairs": {
        "How do mutations in the Omicron variant affect the spike protein's receptor-binding domain (RBD) stability?": [
            "They increase ACE-2 affinity but decrease RBD stability",
            "They increase both ACE-2 affinity and RBD stability",
            "They decrease both ACE-2 affinity and RBD stability",
            "They decrease ACE-2 affinity but increase RBD stability"
        ],
        "What aspect of the spike protein remains largely unaffected by mutations, preserving innate immune recognition across variants?": [
            "Recognition by mannose-binding lectin (MBL)",
            "Recognition by neutralizing antibodies",
            "Binding affinity to ACE-2",
            "Protein stability"
        ],
        "What is the primary target for neutralizing antibodies and is used in most vaccines against SARS-CoV-2?": [
            "The spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "What strategy is suggested for designing nanobodies to enhance cross-variant efficacy against SARS-CoV-2?": [
            "Targeting conserved regions recognized by MBL",
            "Targeting highly mutable regions in the RBD",
            "Focusing solely on increasing binding affinity",
            "Avoiding regions affected by the glycan shield"
        ],
        "Which variants of SARS-CoV-2 have accumulated over 30 mutations in the spike protein, enhancing ACE-2 binding affinity and immune evasion?": [
            "Omicron variants (BA.1 and BA.2)",
            "Delta variant",
            "Alpha variant",
            "Beta variant"
        ]
    }
}